Eisai CEO Outlines Ambitions for Alzheimer’s Drug Leqembi After FDA Approval
Following US FDA approval for Japan-based Eisai Co., Ltd (TYO: 4523) and Biogen Inc’s (NASDAQ:...
Drug
Dizal’s Sunvozertinib and Golidocitinib Combo Gets NMPA Approval for Phase II Study
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving approval from the National Medical...
Luye Pharma’s BA1301 Receives CDE Approval for Clinical Trials
China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval from the Center...
HutchMed’s Sovleplenib Administered to First Patient in Phase II COVID-19 Study
On January 4, Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) administered its novel, investigational,...
Salubris Pharmaceuticals Gains NMPA Approval for Phase I Study of SAL0133
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving approval from the National...
Henlius Completes First Dosing in Global Phase III Study for HanSiZhuang in LS-SCLC
Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...
Boehringer Ingelheim Enrolls First Patient in Phase II/III Study for BI 907828
German pharmaceutical giant Boehringer Ingelheim has announced the enrollment of the first patient in the...
Vcanbio’s Stem Cell Therapy VUM02 Accepted for Clinical Trial Review
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical...
CanSino Biologics’ mRNA Vaccine CS-2034 Shows Positive Safety and Immunogenicity Data
China-based CanSino Biologics (HKG: 6185) has announced positive periodical data from a clinical study assessing...
Jiangsu Aidea’s ACC007 Approved by NMPA for HIV-1 Treatment
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that its Category 1 compound...
Haisco’s EGFR-PROTAC HSK40118 Accepted for Review by China’s NMPA
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its clinical trial filing...
EOC Pharma’s Entinostat NDA Accepted by China’s NMPA for Breast Cancer
EOC Pharma, a biotech company operating in the US and China, has announced that its...
Transcenta’s TST003 Receives Clinical Trial Approval in China and US
China – based biopharma Transcenta Holding Ltd (HKG: 6628) has announced that it has received...
Henlius’ Hanbeitai Gains NMPA Approval for Expanded Indications
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that the National Medical Products Administration (NMPA)...
HutchMed Completes Enrollment for Phase III ESLIM-01 Study of Sovleplenib in ITP
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment...
RemeGen’s RC48 Gains NMPA Approval for Phase II Study in Bladder Cancer
China – based biopharmaceutical company RemeGen Ltd (HKG: 9995) has announced that it has received...
Jiangxi Jemincare Gains FDA Approval for Clinical Trial of JYB1907 in Solid Tumors
China – based Jiangxi Jemincare Group has announced that it has received approval from the...
Mabwell Receives NMPA Approval for Clinical Trial of 9MW3011 in Rare Diseases
China – based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has...
Staidson’s Anti-C5a Monoclonal Antibody STSA-1002 Accepted for NMPA Review
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced that the clinical trial filing...
Junshi Biosciences’ CGRP Monoclonal Antibody JS010 Accepted for NMPA Review
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that the clinical trial filing for...